Welcome to Q4: A blank slate awaits!

What’s on tap for the next three months of biotech? We’re waiting with bated breath on some compelling trial data — Esperion Therapeutics, for instance, has a Phase 3 readout coming soon that could decide whether its cholesterol drug is a safe product, or a colossal waste.

We’ll hear, too, whether Sage Therapeutics’ postpartum depression drug will win over the FDA, whether Spark Therapeutics’ hemophilia A gene therapy has any legs, and lots more.

We have all the details you need to know in our fourth-quarter biotech scorecard. (And we're working up some delightful emojis to populate it as well.)